Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2013; 19(48): 9282-9293
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9282
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9282
Table 3 Clinical and pathological characteristics of the 136 patients treated with neoadjuvant chemotherapy for esophageal and gastro-esophageal adenocarcinoma, classified as responders Tumour regression grade 1-2 or non-reponders tumour regression grade 3-5 n (%)
TRG 1-2 36 (26.5) | TRG 3-5 100 (73.5) | Pvalue | ||
Preoperative status | ||||
Age (range) yr1 | 65.27 (26.99-76.04) | 63.51 (32.77-81.28) | 0.410 | |
Sex ratio (M:F)1 | 32 (88.9):4 (11.1) | 86 (86):14 (14) | 0.662 | |
cT stage | 1 | 0 (0) | 0 (0) | 0.396 |
2 | 2 (5.6) | 14 (14) | ||
3 | 33 (91.7) | 81 (81) | ||
4 | 1 (2.8) | 5 (5) | ||
cN stage | 0 | 5 (13.9) | 14 (14) | 0.987 |
1 | 31 (86.1) | 86 (86) | ||
cM stage | 0 | 35 (97.1) | 99 (99) | 0.456 |
1 | 1 (2.8) | 1 (1) | ||
Performance status | 0 | 12 (33.3) | 23 (23) | 0.225 |
1 | 23 (63.9) | 73 (73) | ||
2 | 1 (2.8) | 4 (4.0) | ||
ASA | 1 | 2 (5.6) | 9 (9.1) | 0.408 |
2 | 32 (88.9) | 74 (74.7) | ||
3 | 2 (5.6) | 16 (16.2) | ||
O-POSSUM | 15 (12-23) | 16 (12-26) | 0.476 | |
Tumour site | Middle 1/3 | 1 (2.8) | 0 (0) | 0.738 |
Lower 1/3 | 15 (41.7) | 42 (42) | ||
GEJ-S1 | 7 (19.4) | 16 (16) | ||
GEJ-S2 | 9 (25) | 25 (25) | ||
GEJ-S3 | 4 (11.1) | 16 (16) | ||
Operative outcomes | ||||
Length of operation (min)1 | 262 (163-427) | 260 (120-471) | 0.513 | |
Blood loss (mL)1 | 300 (0-3000) | 325 (0-1700) | 0.673 | |
Clavien Dindo Max | 0 | 14 (38.9) | 39 (39.4) | 0.531 |
1 | 2 (5.6) | 6 (6.1) | ||
2 | 14 (38.9) | 26 (26.3) | ||
3 | 4 (11.1) | 13 (13.1) | ||
4 | 2 (5.6) | 15 (15.2) | ||
5 | 0 (0) | 0 (0) | ||
Anastomotic leaks | 1 (2.8) | 8 (8.1) | 0.276 | |
Pathological outcomes | ||||
yPT | 0 | 8 (22.2) | 0 (0) | < 0.0001 |
1 | 11 (30.6) | 12 (12) | ||
2 | 9 (25) | 25 (25) | ||
3 | 8 (22.2) | 58 (58) | ||
4 | 0 (0) | 5 (5) | ||
yPN | 0 | 34 (94.4) | 39 (39) | < 0.0001 |
1 | 0 (0) | 21 (21) | ||
2 | 2 (5.6) | 23 (23) | ||
3 | 0 (0) | 17 (17) | ||
yPM | 0 | 36 (100) | 100 (100) | 0.579 |
Nodal downstaged (cN1 to ypN0) | 30 (83.3) | 30 (30) | < 0.0001 | |
Positive nodes1 | 0 (0-5) | 1 (0-24) | < 0.0001 | |
Nodal yield1 | 18 (4-25) | 18 (3-53) | 0.984 | |
Resection clearance | R0 | 35 (97.2) | 75 (75) | 0.004 |
Vascular invasion | 4 (11.1) | 37 (37) | 0.004 | |
Lymphatic invasion | 4 (11.1) | 18 (18) | 0.338 | |
Perineural invasion | 2 (5.6) | 18 (18) | 0.072 | |
Maximum tumour diameter1 | (mm) | 15 (0-110) | 30 (0-155) | < 0.0001 |
Morphology | Ulcer | 30 (93.8) | 66 (68) | 0.003 |
Polypoid | 2 (6.3) | 21 (21.6) | ||
Fungating | 0 (0) | 3 (3.1) | ||
Diffuse infiltrating | 0 (0) | 7 (7.2) | ||
Grade | G1 | 8 (22.2) | 8 (8) | 0.104 |
G2 | 9 (25) | 28 (28) | ||
G3 | 19 (52.8) | 63 (63) | ||
G4 | 0 (0) | 1 (1) | ||
Sites of recurrence | Local | 0 (0) | 8 (8.1) | 0.080 |
Nodal | 1 (2.8) | 13 (13.1) | 0.082 | |
Distant | 2 (5.6) | 42 (42.4) | < 0.0001 |
- Citation: Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013; 19(48): 9282-9293
- URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9282.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9282